Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 336Neoplasms, Plasma Cell 99Myelodysplastic Syndromes 89Leukemia, Lymphocytic, Chronic, B-Cell 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 88Hodgkin Disease 85Lymphoma, Non-Hodgkin 84Leukemia, Myeloid, Acute 83Lymphoma, Follicular 71Leukemia 71Lymphoma 69Lymphoma, Mantle-Cell 67Lymphoma, B-Cell, Marginal Zone 63Burkitt Lymphoma 63Lymphoma, Large B-Cell, Diffuse 59Lymphoma, Large-Cell, Immunoblastic 55Recurrence 52Myeloproliferative Disorders 49Leukemia, Myeloid, Chronic-Phase 48Primary Myelofibrosis 46Leukemia, Myeloid, Accelerated Phase 43Leukemia, Myelomonocytic, Chronic 41Leukemia, Myelogenous, Chronic, BCR-ABL Positive 38Dendritic Cell Sarcoma, Interdigitating 37Congenital Abnormalities 35Blast Crisis 34Waldenstrom Macroglobulinemia 27Myelodysplastic-Myeloproliferative Diseases 25Lymphoma, T-Cell, Cutaneous 25Immunoglobulin Light-chain Amyloidosis 25

Interventions

Lenalidomide 2Dexamethasone 2Bortezomib 2carfilzomib 1belinostat 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Marrow Neoplasms × Cyclophosphamide × Plasma cell × Clear all
NCT00908232 2015-01-15

SEQUENTIAL

Janssen-Cilag International NV

Phase 2 Completed
163 enrolled 11 charts
Plasma cell

Multiple Myeloma, Disease Progression, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡